LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 6 of 15: Mean cell count and mean growth rate across biological replicate 3. - Dataset (ID:20242)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | A443654 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 931 | 4223 | 0.2206 | -0.1665 |
| SK-BR-3 | OSI-027 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1658 | 4223 | 0.3928 | 0.0911 |
| SK-BR-3 | XMD11-85h | 10.0 | uM | LJP6 | 72 | hr | 1401 | 3243 | 4223 | 0.7681 | 0.6529 |
| SK-BR-3 | HG-6-64-01 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 516 | 4223 | 0.1222 | -0.3138 |
| SK-BR-3 | WH-4-025 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1181 | 4223 | 0.2798 | -0.0779 |
| SK-BR-3 | WZ-4-145 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1095 | 4223 | 0.2594 | -0.1085 |
| SK-BR-3 | XMD16-144 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1171 | 4223 | 0.2773 | -0.0817 |
| SK-BR-3 | Brivanib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 4050 | 4223 | 0.9590 | 0.9387 |
| SK-BR-3 | Buparlisib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 978 | 4223 | 0.2317 | -0.1500 |
| SK-BR-3 | BX-912 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1404 | 4223 | 0.3326 | 0.0011 |
| SK-BR-3 | Canertinib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1094 | 4223 | 0.2591 | -0.1090 |
| SK-BR-3 | Celastrol | 10.0 | uM | LJP6 | 72 | hr | 1401 | 1126 | 4223 | 0.2666 | -0.0977 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1063 | 4223 | 0.2517 | -0.1200 |
| SK-BR-3 | CGP60474 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 696 | 4223 | 0.1650 | -0.2498 |
| SK-BR-3 | CHIR-99021 | 10.0 | uM | LJP6 | 72 | hr | 1401 | 3218 | 4223 | 0.7620 | 0.6438 |
| SK-BR-3 | CP724714 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1398 | 4223 | 0.3310 | -0.0012 |
| SK-BR-3 | CP466722 | 10.0 | uM | LJP5 | 72 | hr | 1401 | 2026 | 4223 | 0.4798 | 0.2214 |
| SK-BR-3 | Crizotinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1239 | 4223 | 0.2935 | -0.0574 |
| SK-BR-3 | Momelotinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1632 | 4223 | 0.3866 | 0.0819 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1770 | 4223 | 0.4193 | 0.1308 |
| SK-BR-3 | Dasatinib | 10.0 | uM | LJP6 | 72 | hr | 1401 | 900 | 4223 | 0.2131 | -0.1778 |
| SK-BR-3 | Dovitinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1873 | 4223 | 0.4437 | 0.1673 |
| SK-BR-3 | Enzastaurin | 10.0 | uM | LJP5 | 72 | hr | 1401 | 4209 | 4223 | 0.9967 | 0.9951 |
| SK-BR-3 | Erlotinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 2060 | 4223 | 0.4878 | 0.2334 |
| SK-BR-3 | Foretinib | 10.0 | uM | LJP5 | 72 | hr | 1401 | 1352 | 4223 | 0.3201 | -0.0176 |